Press Release Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072 Aug 25
Press Release Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa Aug 10
Press Release Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Aug 4